The DOI matches its Crossref record; 93 of the 100 references it cites were found in a registry or an index; 60 of the 81 sources its claims cite were checked for support.
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Open accessPublished version of a preprint
Abstract
KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS, and amplifications of KRASG12C, MYC, MET, EGFR, and CDK6 emerged at acquired resistance. In PDAC cell lines and organoid models treated with the KRASG12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associate with resistance to therapy. MRTX1133 treatment of the KrasLSL-G12D/+; Trp53LSL-R172H/+; p48-Cre (KPC) mouse model yielded deep tumor regressions, but drug resistance ultimately emerged, accompanied by amplifications of Kras, Yap1, Myc, Cdk6, and Abcb1a/b, and co-evolution of drug-resistant transcriptional programs. Moreover, in KPC and PDX models, mesenchymal and basal-like cell states displayed increased response to KRAS inhibition compared to the classical state. Combination treatment with KRASG12D inhibition and chemotherapy significantly improved tumor control in PDAC mouse models. Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies. Significance: Acquired resistance may limit the impact of KRAS inhibition in patients with PDAC. Using clinical samples and multiple preclinical models, we define heterogeneous genetic and non-genetic mechanisms of resistance to KRAS inhibition that may guide combination therapy approaches to improve the efficacy and durability of these promising therapies for patients. See related commentary by Marasco and Misale, p. 2018.
Overview
CoChat Summary
TL;DR
This multimodal study defines heterogeneous genetic and non-genetic resistance mechanisms to mutant-selective KRAS inhibition in pancreatic ductal adenocarcinoma (PDAC), using patient ctDNA and preclinical models. It finds recurrent RTK–RAS/PI3K pathway alterations, cell-cycle/efflux amplifications, and a drug-resistant partial EMT cell state, supporting combination strategies with chemotherapy or RTK/CLDN18.2-directed agents.
Key findings
- In 22 patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, 18/22 (81%) had PR/SD and acquired resistance, 4/22 had primary resistance, and putative genetic resistance mechanisms were identified in 9/22 (41%); across an aggregate KRASG12C cohort, genetic mechanisms were found in 51% of NSCLC, 52% of CRC, 46% of PDAC, and 75% of other GI cancers, while no putative genetic mechanism was identified in 54% of PDAC, 49% of NSCLC, and 48% of CRC.
- In preclinical models, MRTX1133 selectively inhibited KRASG12D-mutant cells across 877 PRISM cell lines; among 46 KRASG12D lines, 22 were sensitive and 24 resistant by AUC, with resistance associated with EMT, RTK–RAS pathway gene copy gains, PI3K–AKT–mTOR activation, and MYC/cell-cycle signatures.
- In the autochthonous KPC GEMM, MRTX1133 prolonged median survival to 10.7 weeks versus 1 week for vehicle (P = 2.08e–6), with complete responses in 67% (10/15), PRs in 27% (4/15), and primary resistance in 1/15; 55% (6/11) of endpoint MRTX1133-resistant tumors had high-level amplifications including Myc, Kras, Yap1, and Cdk6/Abcb1a/b.
- Single-nucleus RNA-seq of 68,479 nuclei showed MRTX1133-resistant tumors shifted toward pEMT (60% of nuclei) and mesenchymal (30%) states, and combination MRTX1133 plus gemcitabine/n(ab)-paclitaxel prevented relapse in orthotopic and metastatic models, with no lung metastases in combination-treated mice in the established-metastasis assay.
Methods
- Patient ctDNA from pretreatment and end-of-therapy plasma was sequenced from patients with KRASG12C-mutant PDAC treated on KRYSTAL-1 (adagrasib) or CodeBreaK100 (sotorasib), plus additional GI cancer samples and previously published KRASG12C inhibitor resistance cohorts.
- Preclinical profiling included PRISM multiplex cell-line screening (877 lines), KRASG12D-mutant PDAC patient-derived organoids (n = 20), isogenic MRTX1133-resistant cell lines, KPC GEMMs, PDX models, WES, bulk RNA-seq, snRNA-seq, RPPA, RTK arrays, immunoblots, IHC, and multiplex immunofluorescence.
- Analyses included AUC/dose-response modeling, GSEA, NMF metaprogram identification, inferCNV, pySCENIC regulon analysis, Markov absorption-based cell-state classification, and survival/statistical comparisons as described.
Limitations
- Stated: human PDAC resistance analysis relied primarily on ctDNA, and the authors note that future biopsies from patients progressing on RAS inhibitors are needed to fully interrogate genetic and non-genetic resistance.
- Stated: preclinical studies focused on the KRASG12D inhibitor MRTX1133; resistance mechanisms need evaluation with pan-RAS/pan-KRAS inhibitors and drugs of different selectivity/mechanism to define cross-resistance patterns.
- Evident from the text: the patient cohort is described as rare and limited to 22 PDAC patients, ctDNA-based detection may miss resistance drivers, and some resistant tumors/subclones lacked identifiable genomic drivers, leaving non-genetic mechanisms incompletely resolved.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
28 Valid · 0 Not valid · 6 Not checked · 168 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Additional investigations of combination therapy strategies with MRTX1133 in preclinical models of PDAC have suggested that co-targeting of EGFR may have enhanced efficacy over monotherapy (30, 34).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Introduction
What the sources say
- Supportedcites [30] Hallin, 2022, Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor, Nat Med source
In the section on cetuximab combinations, the paper reports that cetuximab, an EGFR-targeting antibody, improved the anti-tumor efficacy of MRTX1133 over either agent alone in all seven pancreatic or colon xenograft models evaluated. It also reports stronger pathway inhibition in the AsPC-1 pancreatic cancer model, supporting the claim's qualified statement about preclinical PDAC models. (LLM, conf=0.94)
- Supportedcites [34] Gulay, 2023, Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma, Cancer Res source
The “Irreversible pan-ERBB inhibitors synergize with MRTX1133 in vitro” section reports synergy in PDAC models with EGFR-targeting agents, although it was less consistent than with pan-ERBB inhibition. The “KRAS G12D-mutant PDAC cells” section reports greater tumor-growth inhibition with MRTX1133 plus afatinib than with MRTX1133 alone in transplant models. Together, these findings support the hedged claim of enhanced efficacy, with the qualification that the strongest evidence is for pan-ERBB rather than EGFR-only inhibition. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although these early clinical trial results need to be confirmed in larger studies, the efficacy of sotorasib and adagrasib in advanced, chemotherapy-treated disease compares favorably to historical data on second-line chemotherapy efficacy in PDAC, where response rates are consistently less than 10% and median PFS is less than 3 months (28, 29).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Introduction
What the sources say
- Not checked — no full text of the sourcecites [28] Wang-Gillam, 2019, NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors, Eur J Cancer source
- Partly supportedcites [29] Huffman, 2023, Effect of a MUC5AC antibody (NPC-1C) administered with second-line gemcitabine and nab-paclitaxel on the survival of patients with advanced pancreatic ductal adenocarcinoma: a randomized clinical trial, JAMA Netw Open sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates an associationn = 38- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent preclinical work with MRTX1133 has demonstrated excellent responses in cell line and xenograft models of PDAC (30, 32).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Introduction
What the sources say
- Supportedcites [30] Hallin, 2022, Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor, Nat Med source
The section on KRASG12D-mutant cancer cell lines reports potent inhibition of cell viability by MRTX1133. The xenograft-results section reports at least 30% tumor regression in 8 of 11 pancreatic cancer models. Our copy provides no page numbers for these passages. (LLM, conf=0.92)
- Supportedcites [32] Mahadevan, 2023, KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells, Cancer Cell source
The section ‘KRAS* inhibition suppresses the growth of human PDAC cells’ (page not available) reports that MRTX1133 inhibited proliferation in KRAS G12D-mutant PDAC cell lines. It also reports significantly reduced tumor weights in orthotopic xenografts and tumor control or slight regression in all eight patient-derived xenografts. (LLM, conf=0.91)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Patient data suggest that the classical subtype of PDAC responds better to chemotherapy than the poorly prognostic basal-like PDAC subtype (44, 58, 59).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Efficacy of Combination Chemotherapy with KRASG12D Inhibition in PDAC
What the sources say
- Supportedcites [44] Raghavan, 2021, Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer, Cell source
The Results section, “State-specific TME signals drive transcriptional heterogeneity and drug response” (page unavailable), reports clinical trial data in which patients with basal phenotypes tended to have poorer outcomes with combination chemotherapy. It also reports that organoids in a basal state were less sensitive to several chemotherapies than when they returned to a classical state. Together, these support the claim’s cautious comparison. (LLM, conf=0.91)
- Supportedcites [58] Aung, 2018, Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial, Clin Cancer Res source
The Results report more partial responses to first-line chemotherapy in classical than basal-like tumors (13/38 versus 1/12). The Discussion explicitly states that patients with advanced classical PDAC responded better than those with basal-like PDAC; the Results also report shorter survival for the basal-like subtype. Page numbers are not provided in our copy. (LLM, conf=0.94)
- Supportedcites [59] O’Kane, 2020, GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer, Clin Cancer Res source
The ‘Response to chemotherapy according to modified Moffitt classification’ section reports a higher overall response rate in classical than basal-like PDAC (33% versus 10%, p=0.02). The ‘Overall survival’ section reports shorter survival for the basal-like subgroup receiving mFFX and identifies subtype as prognostic; it found no survival difference between subgroups receiving GnP, so the claim is appropriately framed as a suggestion rather than a benefit with every regimen. (LLM, conf=0.92)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Finally, we identified a novel partial EMT (pEMT) signature analogous to previously described hybrid states along the epithelial–mesenchymal axis (Supplementary Fig. S8A; refs. 50, 53).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Malignant Cell State Evolution in Response and Resistance to KRASG12D Inhibition
What the sources say
- Not checked — no full text of the sourcecites [50] Gavish, 2023, Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours, Nature source
- Supportedcites [53] Barkley, 2022, Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment, Nat Genet source
The Results describe a partial mesenchymal (pEMT) module distinct from a complete mesenchymal module and note that pEMT had previously been characterized in other cancer types. This supports the citation’s comparison to previously described partial EMT states; the citing authors’ identification of a novel signature is their own finding, not a finding attributed to this source. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
104 more claims · 7 with their cited sources checked
Create a free account to see all 202 claims and every source verdict.
- It may state two separate claims as one. 68
- Probably not a substantial claim. 32
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the established role of lineage plasticity in resistance to KRAS-targeted therapies,26–31 effective therapeutic interventions targeting drivers of lineage plasticity remain lacking.”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Differentiation into alveolar type 1 (AT1)-like,26 squamous,27,28 as well as mucinous states29 has been implicated to contribute to KRAS inhibitor tolerance in lung adenocarcinoma, whereas transition into a classical state is observed in PDAC cells surviving KRAS-targeted therapy.30,31”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lineage plasticity has emerged as a critical mechanism of non-genetic resistance to KRAS-targeted therapies in NSCLC and PDAC.27–31”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In NSCLC, KRAS-mutant tumors evade therapy through transition into AT1-like,29 squamous,27,28 or mucinous states,29 while pancreatic cancer cells adopt a classical epithelial state to bypass KRAS inhibition.30,31”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic alterations, especially secondary RAS mutations, have been identified as one of the most common mechanisms of acquired resistance to KRAS inhibitors in patients [49, 51–55].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [55]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Methods > In Vivo Protocols
“100% to 76% = 4”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Methods > In Vivo Protocols
“51% to 76% = 3”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Efficacy of Combination Chemotherapy with KRASG12D Inhibition in PDAC
“In vivo, 6649C2-LM implanted subcutaneously grows slightly more rapidly than the parental cell line, showing overall more aggressive growth and faster outgrowth under MRTX1133 treatment (Fig. 6D).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Efficacy of Combination Chemotherapy with KRASG12D Inhibition in PDAC
“We previously generated a transplantable cell line model of metastatic PDAC (6694C2-LM) by isolating and culturing a tumor nodule from a spontaneous lung metastasis of a 6649C2 tumor-bearing mouse (60).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Genetic Mechanisms of Resistance to KRASG12C Inhibition in Patients with PDAC
“C, Co-mutation plot displaying pathogenic and likely pathogenic treatment-emergent variants and genomic amplification of putative drivers of resistance detected in ctDNA samples from PDAC patients with acquired resistance to adagrasib (patients 1–8) or sotorasib (patients 9–22).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Genetic Mechanisms of Resistance to KRASG12C Inhibition in Patients with PDAC
“Primary resistance with PD was observed in 4/22 patients (patients 1, 9, 10, 11).”
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“79 ; version 1.38.3) log-normalized tumor-derived expression profiles.”
InfluentialFiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890 · cited 1×
“Finally, individual dot densitometry analysis was conducted using Fiji image analysis software (83). snRNA-seq Sample Preparation, Library Generation, and Sequencing.”
MethodNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“…was determined based on routine clinical evaluation by a blinded, board-certified radiologist and defined as SD for at least 12 weeks or a partial or complete response followed by disease progression based on Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 for CT imaging (75).”
MethodInfluentialSiegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationHingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609 · cited 1×
“After evaluating features of response and resistance to MRTX1133 in vitro , we sought to investigate the efficacy of KRAS G12D inhibition in the immunocompetent, autochtho-nous KPC ( Kras LSL-G12D/ + ; Trp53 LSL-R172H/ + ; p48-Cre ) genetically engineered mouse model (GEMM) of PDAC (49).”
BackgroundHidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 2×
“…published cases of lung neuroendocrine tumor (patient 105; 14), melanoma, small cell lung cancer and spindle cell carcinoma (patients 10, 21 and 8; 19) to create a pan-cancer cohort of 132 patients with KRAS G12C mutation and displaying acquired resistance to adagrasib, sotorasib, or…”
BackgroundData-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E.-A. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.047 · Cited by 2,303 · cited 1×
“54).”
Cited by
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 145
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Yu, B., Shao, S., & Ma, W. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217350 · Cited by 131
Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer
Pei, G., Min, J., Rajapakshe, K., Branchi, V., Liu, Y., Selvanesan, B. C., Thege, F. I., Sadeghian, D., Zhang, D., Cho, K. S., et al. (2025) · Nature · doi:10.1038/s41586-025-08927-x · Cited by 144
“5), along with CAFs previously established from patients with PDAC 16,25,26 .”
Self-citationConsensus, debate, and prospective on pancreatic cancer treatments
Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 109
Self-citation
Metadata
- Authors
- Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., Uribe, G. A., Yang, A., Kapner, K. S., Hambitzer, F. P., Qiang, L., Feng, H., Geisberg, J., Wang, J., Evans, K. E., Lyu, H., Schalck, A., Feng, N., Lopez, A. M., Bristow, C. A., Kim, M. P., Rajapakshe, K. I., Bahrambeigi, V., Roth, J. A., Garg, K., Guerrero, P. A., Stanger, B. Z., Cristea, S., Lowe, S. W., Baslan, T., Van Allen, E. M., Mancias, J. D., Chan, E., Anderson, A., Katlinskaya, Y. V., Shalek, A. K., Hong, D. S., Pant, S., Hallin, J., Anderes, K., Olson, P., Heffernan, T. P., Chugh, S., Christensen, J. G., Maitra, A., Wolpin, B. M., Raghavan, S., Nowak, J. A., Winter, P. S., Dougan, S. K., & Aguirre, A. J.
- Affiliations
- Broad Institute (US)
- Harvard University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- 3Harvard Medical School, Boston, Massachusetts.
- 8Exact Sciences, Redwood City, California.
- University of Pennsylvania (US)
- Memorial Sloan Kettering Cancer Center (US)
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Amgen (United States) (US)
- Mirati Therapeutics (United States) (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Aguirre, Andrew J.
- ORCID
- Dilly, Julien
- Hoffman, Megan T.
- Abbassi, Laleh
- Li, Ziyue
- Paradiso, Francesca
- Parent, Brendan D.
- Hennessey, Connor J.
- Jordan, Alexander C.
- Morgado, Micaela
- Dasgupta, Shatavisha
- Uribe, Giselle A.
- Yang, Annan
- Kapner, Kevin S.
- Hambitzer, Felix P.
- Qiang, Li
- Feng, Hanrong
- Geisberg, Jacob
- Wang, Junning
- Evans, Kyle E.
- Lyu, Hengyu
- Schalck, Aislyn
- Feng, Ningping
- Lopez, Anastasia M.
- Bristow, Christopher A.
- Kim, Michael P.
- Rajapakshe, Kimal I.
- Bahrambeigi, Vahid
- Roth, Jennifer A.
- Garg, Kavita
- Guerrero, Paola A.
- Stanger, Ben Z.
- Cristea, Simona
- Lowe, Scott W.
- Baslan, Timour
- Van Allen, Eliezer M.
- Mancias, Joseph D.
- Chan, Emily
- Anderson, Abraham
- Katlinskaya, Yuliya V.
- Shalek, Alex K.
- Hong, David S.
- Pant, Shubham
- Hallin, Jill
- Anderes, Kenna
- Olson, Peter
- Heffernan, Timothy P.
- Chugh, Seema
- Christensen, James G.
- Maitra, Anirban
- Wolpin, Brian M.
- Raghavan, Srivatsan
- Nowak, Jonathan A.
- Winter, Peter S.
- Dougan, Stephanie K.
- Aguirre, Andrew J.
- Venue
- Cancer Discovery
- Published
- 2024-07-05
- Volume
- 14
- Issue
- 11
- Pages
- 2135-2161
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC11528210
- OpenAlex
- W4400416998
- Semantic Scholar
- 5523d24bee9ee8e296cf3c0bde017f0d9fee7408
- Cited by
- 308
- References
- 100
- Citations by year
- 2026: 162 · 2025: 129 · 2024: 17
- FWCI
- 54.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- Break Through Cancer
- National Cancer Institute (R01 CA276268, U01 CA274276, P50CA127003, P50CA221707, R01CA218230)
- Hale Family Center for Pancreatic Cancer Research
- Lustgarten Foundation
- Pancreatic Cancer Action Network
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS inhibition, acquired drug resistance, pancreatic ductal adenocarcinoma, KRAS G12C, KRAS G12D, adagrasib, sotorasib, MRTX1133, PIK3CA mutation, PI3K/AKT/mTOR pathway, epithelial-mesenchymal transition, KPC mouse model, organoid models, combination therapy, chemotherapy, YAP, c-Myc, CDK6, non-genetic resistance, drug resistance mechanisms
- MeSH terms
- Animals, Humans, Mutation, Pancreatic Neoplasms, Pyrimidines, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-24-0177
- The paper
- Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., Uribe, G. A., Yang, A., Kapner, K. S., Hambitzer, F. P., Qiang, L., Feng, H., Geisberg, J., Wang, J., Evans, K. E., . . . Aguirre, A. J. (2024). Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-24-0177
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.